Lupus News and Research

Latest Lupus News and Research

GSK submits BENLYSTA MAA for systemic lupus erythematosus

Human Genome Sciences, Inc. today announced that GlaxoSmithKline (GSK) has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for approval to market BENLYSTA® (belimumab) for the treatment of systemic lupus erythematosus (SLE).

7 Jun 2010

New study provides cause-and-effect link between immune system cells and mental illness

A Nobel Prize-winning University of Utah geneticist discovered that bone marrow transplants cure mutant mice who pull out their hair compulsively. The study provides the first cause-and-effect link between immune system cells and mental illness, and points toward eventual new psychiatric treatments.

28 May 2010

La Jolla Pharmaceutical announces $16.3 million private placement

La Jolla Pharmaceutical Company announced today that the Company has entered into definitive agreements with institutional investors and affiliates for a private placement of common stock, convertible preferred stock and warrants to purchase convertible preferred stock totaling up to $16.3 million in gross proceeds.

25 May 2010

Vaccinations recommended for adults

Yearly vaccinations aren't just for kids any more. You probably heard a lot about a seasonal or H1N1 flu shot last fall, but you should know that a battery of other adult vaccinations might also become part of your health care routine. Pneumonia and shingles vaccines are preventive-care essentials for older adults, and meningitis and tetanus shots are now college rites of passage. Even the vaccines of childhood—measles, mumps and rubella, and whooping cough—are recommended for adults who missed out in their younger years.

19 May 2010

Roche, Biogen Idec discontinue ocrelizumab clinical development programme for RA

Roche and Biogen Idec today announced their decision to discontinue the ocrelizumab clinical development programme in patients with rheumatoid arthritis (RA).

19 May 2010

REVEAL risk score calculator provides innovative approach to better understand PAH

Actelion Ltd announced today that findings from the REVEAL Registry have confirmed the clinical utility of the REVEAL risk score calculator, a new tool designed to predict 1-year survival in patients with pulmonary arterial hypertension according to data presented at the American Thoracic Society's Annual International Conference.

18 May 2010

Phase IIb trail results of epratuzumab in lupus patients to be presented at EULAR 2010

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced that clinical trial results on epratuzumab, the anti-CD22 humanized monoclonal antibody licensed to UCB SA, Brussels, for autoimmune disease indications, from the Phase IIb study in patients with lupus, will be presented in four posters sessions and one published abstract.

14 May 2010

Gene-Eden may be effective in reducing Hepatitis C viral load in people infected with virus: Review

A new review on the Amazon website suggests that the natural antiviral supplement Gene-Eden may be effective in reducing the Hepatitis C viral load in people infected with the virus.

13 May 2010

Solta Medical honored with Provectus Award at first annual Bright Lights Conference

Solta Medical, Inc., a global leader in the medical aesthetics market, today announced that it has received the Provectus Award presented by MDB Capital Group at the first annual Bright Lights Conference, the first public company conference to focus exclusively on companies with disruptive and market changing intellectual property (IP).

13 May 2010

Trubion Pharmaceuticals to present promising data from Phase 1 studies of SBI-087, SBI-087

Trubion Pharmaceuticals, Inc. today announced the acceptance of two Phase 1 data presentations on SBI-087 (PF-05230895) at the 2010 annual congress of the European League Against Rheumatism (EULAR) in Rome, Italy. Presentations will include promising data from a Phase 1 study of SBI-087 for the treatment of rheumatoid arthritis (RA) and a Phase 1 study of SBI-087 for the treatment of systemic lupus erythematosus (SLE). Copies of both abstracts are available at http://www.eular.org. SBI-087 is Trubion's next-generation CD20-directed small modular immunopharmaceutical (SMIP™) product candidate and is being developed in collaboration with Pfizer.

13 May 2010

27-year-old sickle cell disease patient undergoes multiple joint replacement surgery

Fortis Hospitals Mulund, Mumbai, performed a multiple joint replacement surgery on a 27 year old young Nigerian patient. Rebacca underwent a hip and a shoulder replacement surgery by Dr. Sachin Bhonsle, Consultant Orthopedic Surgeon, after years of suffering in pain and immobility.

13 May 2010

Immunomedics third-quarter revenues increase to $10.7 million

Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported financial results for the third quarter ended March 31, 2010. The Company also highlighted recent key developments and planned activities for its clinical pipeline.

10 May 2010

Sermo Category Report: About 30% of patients suffer from depression

Sermo, the world's largest online community for physicians, today announced a Sermo Category Report titled Antidepressant Treatment Behaviors. The report surveyed more than 200 primary care physicians and covers a variety of topics including product choice drivers, treatment paths, referring habits, and overall issues in depression management.

6 May 2010

Researchers analyze spine surgery patients' existing comorbdities in relationship to hospital stay, costs

It is estimated that between 75 and 85 percent of all Americans will suffer from low back pain and/or neck pain at some point in their lives. An estimated 12 million Americans suffer from degenerative disc disease, with over one million patients undergoing surgery each year. The cost of treating back pain is currently estimated at more than $100 billion annually in the U.S. Many patients with back pain have comorbidities that impact spine surgery.

5 May 2010

Karolinska Institutet researchers discover new control mechanism in immune system

Researchers at the Swedish medical university Karolinska Institutet have discovered a new control mechanism in our immune system. The discovery is of potential significance to the treatment of serious diseases such as MS (multiple sclerosis), rheumatoid arthritis, and SLE (Systemic lupus erythematosus).

4 May 2010

Lupus Canada to hold annual fundraising event

In the month of May residents in communities across Canada will participate in Lupus Canada's most important public awareness and fundraising event, Walk a Block for Lupus. Lupus Canada and its member organizations are holding their 9th Annual Walk a Block for Lupus campaign in conjunction with World Lupus Day to help increase awareness and funds for lupus.

4 May 2010

Researchers identify new genetic link to systemic scleroderma

An international research consortium including scientists from The University of Texas Health Science Center at Houston (UTHealth) has identified a new genetic link to the systemic form of scleroderma. Researchers believe a thorough understanding of the genetic nature of the disease is crucial to developing a cure.

30 Apr 2010

New data on Cimzia for Crohn’s Disease treatment to be demonstrated at DDW 2010

Studies and analyses of the Crohn’s Disease (CD) treatment Cimzia® (certolizumab pegol) demonstrating new data will be exhibited at Digestive Disease Week (DDW) 2010, taking place in New Orleans from May 1-5, 2010.

30 Apr 2010

Celgene's first-quarter non-GAAP total revenue up 31% to $789 million

Celgene Corporation announced non-GAAP net income of $294.6 million, or non-GAAP diluted earnings per share of $0.63 for the quarter ended March 31, 2010. Non-GAAP net income for the first quarter of 2009 was $205.1 million or non-GAAP diluted earnings per share of $0.44. Based on U.S. GAAP, Celgene reported net income of $234.4 million, or diluted earnings per share of $0.50 for the quarter ended March 31, 2010. GAAP net income for the first quarter of 2009 was $162.9 million, or diluted earnings per share of $0.35.

29 Apr 2010

Human Genome Sciences reports net loss of $47.9M for first-quarter 2010

Human Genome Sciences, Inc. today announced financial results for the quarter ended March 31, 2010, and provided highlights of recent key developments.

29 Apr 2010

Lupus News and Research

Latest Lupus News and Research

GSK submits BENLYSTA MAA for systemic lupus erythematosus

New study provides cause-and-effect link between immune system cells and mental illness

La Jolla Pharmaceutical announces $16.3 million private placement

Vaccinations recommended for adults

Roche, Biogen Idec discontinue ocrelizumab clinical development programme for RA

REVEAL risk score calculator provides innovative approach to better understand PAH

Phase IIb trail results of epratuzumab in lupus patients to be presented at EULAR 2010

Gene-Eden may be effective in reducing Hepatitis C viral load in people infected with virus: Review

Solta Medical honored with Provectus Award at first annual Bright Lights Conference

Trubion Pharmaceuticals to present promising data from Phase 1 studies of SBI-087, SBI-087

27-year-old sickle cell disease patient undergoes multiple joint replacement surgery

Immunomedics third-quarter revenues increase to $10.7 million

Sermo Category Report: About 30% of patients suffer from depression

Researchers analyze spine surgery patients' existing comorbdities in relationship to hospital stay, costs

Karolinska Institutet researchers discover new control mechanism in immune system

Lupus Canada to hold annual fundraising event

Researchers identify new genetic link to systemic scleroderma

New data on Cimzia for Crohn’s Disease treatment to be demonstrated at DDW 2010

Celgene's first-quarter non-GAAP total revenue up 31% to $789 million

Human Genome Sciences reports net loss of $47.9M for first-quarter 2010

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Lupus News and Research

Latest Lupus News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in